Stockscreener 앱 받기
48.51
1.13%
0.54
시간 외 거래:
47.04
-1.47
-3.03%
전일 마감가:
$47.97
열려 있는:
$47.99
하루 거래량:
2.20M
Relative Volume:
1.22
시가총액:
$120.74B
수익:
$53.04B
순이익/손실:
$4.93B
주가수익비율:
15.29
EPS:
3.1735
순현금흐름:
$15.63B
1주 성능:
-4.17%
1개월 성능:
-11.69%
6개월 성능:
-0.33%
1년 성능:
+3.17%
1일 변동 폭
$47.94
$48.67
1주일 범위
$47.45
$50.45
52주 변동 폭
$45.22
$58.97
사노피 ADR Stock (SNY) Company Profile
SNY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| SNY | 48.51 | 120.74B | 53.04B | 4.93B | 15.63B | 3.1735 |
| LLY | 727.20 | 683.37B | 40.86B | 8.37B | -2.28B | 5.4193 |
| NVO | 99.81 | 446.14B | 39.36B | 13.79B | 9.83B | 2.4077 |
| JNJ | 154.77 | 353.35B | 87.70B | 14.68B | 19.03B | 13.47 |
| ABBV | 166.28 | 293.80B | 55.53B | 5.12B | 15.62B | 3.65 |
| MRK | 96.56 | 242.49B | 63.17B | 12.15B | 14.84B | 1.80 |
사노피 ADR Stock (SNY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-07-26 | 재확인 | Argus | Buy |
| 2024-01-23 | 개시 | Morgan Stanley | Equal-Weight |
| 2024-01-16 | 재개 | UBS | Buy |
| 2023-12-05 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2023-10-30 | 다운그레이드 | Stifel | Buy → Hold |
| 2023-09-06 | 업그레이드 | Berenberg | Hold → Buy |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-04-28 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2023-03-27 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2022-12-13 | 재개 | Morgan Stanley | Overweight |
| 2022-08-12 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2022-08-09 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2021-09-27 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2021-01-15 | 개시 | Deutsche Bank | Sell |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-03-17 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2020-03-11 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-02-11 | 개시 | SVB Leerink | Mkt Perform |
| 2020-01-06 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-09-23 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2019-09-20 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2019-09-03 | 개시 | Bernstein | Outperform |
| 2019-08-14 | 업그레이드 | UBS | Neutral → Buy |
| 2018-12-11 | 업그레이드 | Jefferies | Hold → Buy |
| 2018-11-01 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2018-10-09 | 개시 | Guggenheim | Neutral |
| 2018-09-10 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2018-08-10 | 업그레이드 | Citigroup | Neutral → Buy |
| 2018-03-23 | 업그레이드 | Liberum | Hold → Buy |
| 2018-01-23 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2017-12-06 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2017-12-01 | 다운그레이드 | Morgan Stanley | Overweight → Underweight |
| 2017-11-15 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2017-08-30 | 업그레이드 | HSBC Securities | Reduce → Hold |
모두보기
사노피 ADR 주식(SNY)의 최신 뉴스
FDA To Revisit Regeneron/Sanofi's Dupixent For Rare Skin Disease - Benzinga
Communiqué de presse - GlobeNewswire Inc.
T-Cell Lymphoma Pipeline Insight Analysis Report 2024 - GlobeNewswire Inc.
Sanofi Cancels Consumer Healthcare Business Spin-Off - Forbes
Here’s Why Mastercard Incorporated (NYSE: MA) Is An Attractive Investment Right Now - Stocks Register
Sanofi (SNY) Stock Price, News, Quote & History - Yahoo Finance
Weekly Upgrades and Downgrades - InvestorPlace
16 New 4-Star Stocks - Morningstar
Sanofi SA (ADR: SNY) Stock Price Could Reach $63: Morningstar Research - TopNews India
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading - MSN
Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly Beat - Investor's Business Daily
Biliary Tract Cancer Market Research Report 2024-2030 with Analyst Recommendations - GlobeNewswire Inc.
Sanofi, HCA, Colgate-Palmolive lead Friday's earnings lineup By Investing.com - Investing.com Australia
Sanofi, HCA, Colgate-Palmolive lead Friday's earnings lineup - Investing.com
Sanofi Deal Jitters Imperil Stock’s Big Rebound - MSN
Sanofi Negotiating Exclusively With CD&R for Opella 50% Stake Sale - Zacks Investment Research
Proactive news headlines: Ananda, Helix Exploration, Deltic, Light Science Technologies and more - Proactive Investors UK
French govt set to take stake in Sanofi unit after PE sale - Proactive Investors Australia
Sanofi Negotiating Exclusively With CD&R For Opella 50% Stake Sale - Barchart
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading - MSN
Ophthalmic Disease Therapeutics Market Analysis by Age-related Macular Degeneration, Diabetic Macular Edema, & Other Retinal Disorders - GlobeNewswire Inc.
10 Best Blue-Chip Stocks to Buy for the Long Term - Morningstar
Sanofi ADR: A Year of Highs, Lows, and Market Resilience - The InvestChronicle
Ratios Reveal: Breaking Down Sanofi ADR (SNY)’s Financial Health - The Dwinnex
EXK (Endeavour Silver Corp.) may reap gains as insiders became active recently - Knox Daily
Checking in on Clear Channel Outdoor Holdings Inc. (CCO) after recent insiders movement - Knox Daily
Investing in Sanofi ADR (SNY): What You Must Know - Knox Daily
Investing in Replimune Group Inc (REPL) Is Getting More Attractive - Knox Daily
An Analysis of KE Holdings Inc ADR (BEKE)’s Potential Price Growth - Knox Daily
Europe Pruritus Therapeutics Market Size & Outlook, 2030 - Grand View Research
OTC Drug and Dietary Supplement Market Opportunities and Strategies to 2033 - GlobeNewswire Inc.
Precidian to List First ADRhedged Securities in the U.S. on Cboe, Providing Exposure to Individual International Companies with an Embedded Currency Hedge - PR Newswire
The SNY Stock Puzzle: Unraveling Sanofi ADR’s Fluctuating Performance - The InvestChronicle
Regeneron And Sanofi Snag Their $6 Billion-Potential COPD Approval For Dupixent - Investor's Business Daily
사노피 ADR (SNY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.03%
1.71%
자본화:
|
볼륨(24시간):